Download PDF
Thromb Haemost 2000; 84(05): 740-741
DOI: 10.1055/s-0037-1614107
Commentary
Schattauer GmbH

How to Decide on the Optimal Duration of Anticoagulant Therapy in Carriers of the Factor V Leiden Mutation

Saskia Middeldorp
1   From the Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Harry R. Büller
1   From the Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-A, Hjorth M, Linder O, Boberg J. the Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Eng J Med 1995; 332: 1661-5.
    CrossrefPubMedGoogle Scholar
  • 3 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells PS, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Eng J Med 1999; 340: 901-7.
    CrossrefPubMedGoogle Scholar
  • 4 Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Ascani A, Bazzan M, Alatri A, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Iorio A. for the WODIT Investigators. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: the Warfarin Optimal Duration Italian Trial (WODIT). Thromb Haemost 1999; 82: 684-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Int Med 1996; 125: 1-7.
    CrossrefPubMedGoogle Scholar
  • 6 Van den Belt AGM, Hutten BA, Prins MH, Bossuyt PMM. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S. A decision analysis. Thromb Haemost 2000; 84: 758-63.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: costeffectiveness analysis. Thromb Haemost 2000; 84: 752-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ 1998; 316: 95-9.
    CrossrefPubMedGoogle Scholar